Whereas we also detect synergistic effects between Fin56 and Torin 2 on the viability of BC cell lines and a Torin 2-mediated reduction of GPX4 levels, we do not observe an effect of Fin56 treatment on mTOR activation. The gene discussed is GPX4; the disease is breast cancer.